Business Wire

The Estée Lauder Companies and Estée Lauder Brand Announce Partnership With Amanda Gorman

Share

Today, The Estée Lauder Companies Inc. (NYSE:EL) and the Estée Lauder brand announced a three-year partnership with Amanda Gorman, activist, award-winning writer, and the youngest inaugural poet in U.S. history. This is the first such multi-year partnership for Amanda and the first integrated partnership by The Estée Lauder Companies and the Estée Lauder brand to acknowledge and celebrate a new generation of leaders inspiring change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005711/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Estée Lauder Companies and Estée Lauder Brand Announce Partnership With Amanda Gorman (Photo: Business Wire)

As part of this unprecedented partnership, The Estée Lauder Companies will contribute US$3M over three years to support WRITING CHANGE, a special initiative to advance literacy as a pathway to equality, access, and social change. In addition, Amanda will bring her voice of change to the Estée Lauder brand through campaigns debuting in Spring 2022.

“Our company was founded by an extraordinary woman, Estée Lauder, who paved the way for women everywhere to believe anything is possible. Our first of its kind partnership with Amanda was created under these very same trailblazing ideals,” said Jane Hertzmark Hudis, Executive Group President, The Estée Lauder Companies. “Amanda’s powerful presence and inspirational voice brings hope and confidence to the next generation of leaders. Together, we will create real and meaningful impact through literacy, voice, and self-expression.”

The Estée Lauder Companies and Amanda are united in supporting causes for equality and social impact. The WRITING CHANGE initiative is strongly aligned with the goals of The Estée Lauder Companies and The Estée Lauder Companies Charitable Foundation, which focuses on the well-being of diverse global communities, emphasizing women and girls, supported by the pillars of health, education, and the environment.

“I am honored to partner with The Estée Lauder Companies to activate change through literacy, and to represent a brand founded by such an inspiring and daring woman,” said Amanda Gorman. “Mrs. Estée Lauder shattered glass ceilings as a leader in business 75 years ago. Embracing this spirit, I am delighted that our partnership will help inspire women, girls, and all people around the world to do great things, to disrupt, to be confident, and to be future leaders in whatever path they take.”

“Amanda embodies a new generation and demonstrates the importance and influence of voice,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies. “As a company, we are committed to nurturing the leaders and talent of the future, empowering them to use their voices—and to use them loudly. We are thrilled to partner with Amanda as we embark on this collective journey to strengthen our commitment to girls’ education, helping provide the skills needed to be heard around the globe.”

This year, The Estée Lauder Companies and the Estée Lauder brand celebrate 75 years in business, and today the company is the world’s leader in prestige beauty, supported by a global workforce that is 84% female. In March 2021, the company published its commitments to gender equality and women’s advancement, with initiatives committed to levelling the playing field for all genders inside and outside the company.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with women in over 150 countries and territories around the world and at dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view.

About The Estée Lauder Companies Charitable Foundation (ELCCF)
Fueled by our company values and employees’ passions, the mission of ELCCF is to improve the well-being of our diverse global communities, with an emphasis on women and girls. ELCCF focuses our efforts on three pillars: health, education and the environment and make annual grants to organizations in the United States and around the world that align with these pillars.

About Amanda Gorman
Amanda Gorman is the youngest inaugural poet in U.S. history. She is a committed advocate for the environment, racial equality, and gender justice. Amanda’s activism and poetry have been featured on the Today Show, PBS Kids, and CBS This Morning, and in the New York Times, Vogue, and Essence. After graduating cum laude from Harvard University, she now lives in her hometown of Los Angeles. In 2017, Amanda Gorman was appointed the first-ever National Youth Poet Laureate by Urban Word – a program that supports Youth Poets Laureate in more than 60 cities, regions and states nationally. Gorman’s performance of her poem “The Hill We Climb” at the 2021 Presidential Inauguration received critical acclaim and international attention. The special edition of her inaugural poem, “The Hill We Climb,” was published in March 2021 and debuted at #1 on the New York Times, USA Today and Wall Street Journal bestsellers list. Amanda appeared on the cover of TIME magazine in February 2021 and was the first poet to grace the cover of Vogue in their May 2021 issue. She was Porter Magazine's July 2021cover star and received The Artist Impact Award at the 2021 Backstage at the Geffen Awards. Her debut picture book, Change Sings, will be published in September 2021, and her poetry collection, Call Us What We Carry, will release in December 2021. Please visit theamandagorman.com.

Follow @esteelauder on Instagram, Facebook, Twitter, YouTube, and TikTok
Follow @esteelaudercompanies on Instagram, Facebook, and Twitter
Follow @amandascgorman on Instagram

ELC-C
ELC-B

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
rmancini@estee.com

Media Relations:
Catherine Bomboy Dougherty
cdougher@estee.com

Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye